Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure
In a real-world Belgian cohort of multi-refractory UC patients, tofacitinib demonstrated effectiveness in achieving clinical remission by the end of follow-up with no new safety signals identified. These findings support its use in this challenging patient population.
Authors
- Triana Lobatón (ORCID: https://orcid.org/0000-0003-1817-7704)
- S Dewit
- D Franchimont
- Olivier Dewit (ORCID: https://orcid.org/0000-0003-3726-4854)
- Barbara Willandt
- Peter Bossuyt (ORCID: https://orcid.org/0000-0003-4027-7365)
- A Verreth
- Dirk Staessen
- E Macken
- S Vanden Branden
- S Delen
- Anneline Cremer (ORCID: https://orcid.org/0000-0002-2531-268X)
- F D’Heygere (ORCID: https://orcid.org/0000-0003-4004-1096)
- Sophie Vieujean (ORCID: https://orcid.org/0000-0002-1859-7146)
- Evelien Humblet
- Steven De Coninck
- Jean‐François Rahier (ORCID: https://orcid.org/0000-0002-7738-0238)
- A Vijverman
- Ahmed M. Mansour (ORCID: https://orcid.org/0000-0003-1068-9131)
- N Schoofs
- C Croonen
- Joris Dutré
- C. Thienpont (ORCID: https://orcid.org/0009-0005-2263-1422)
- Fazia Mana (ORCID: https://orcid.org/0000-0002-9203-5176)
- Filip Baert
- J L Coenegrachts
- P Van Hootegem
- Abdo El Nawar
Institutions
- AZ Groeninge (BE)
- Ghent University Hospital (BE)
- Erasmus Hospital (BE)
- CHU Dinant Godinne UCL Namur (BE)
- Centre Hospitalier Universitaire de Liège (BE)
- Imelda Hospital (BE)
- AZ Delta (BE)
- Centre hospitalier régional de la Citadelle (BE)
- AZ Sint-Lucas (BE)
Publication Details
- Journal
- Acta Gastro Enterologica Belgica
- Published
- 2025-09-30
- DOI
- https://doi.org/10.51821/88.3.14064
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- Celgene
- Centre International de Recherche sur le Cancer
- Celltrion